CYTOMX THERAPEUTICS (CTMX) Covered Calls

You can sell covered calls on CYTOMX THERAPEUTICS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CTMX (prices last updated Mon 4:16 PM ET):

CYTOMX THERAPEUTICS (CTMX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
15.92 +0.13 15.80 18.98 649K - 0.7B
Covered Calls For CYTOMX THERAPEUTICS (CTMX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 15 0.20 18.78 -20.1% -1467.3%
Nov 16 15 1.10 17.88 -16.1% -178.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California